Iterum Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Iterum Therapeutics reported a productive Type A meeting with the FDA regarding the potential resubmission of its NDA for oral sulopenem, aimed at treating uncomplicated urinary tract infections (uUTI). A Type B meeting has been requested to finalize the design for an additional Phase 3 trial. Financially, the company has $85.7 million in cash, sufficient to fund operations into 2024. The third-quarter net income was $3.7 million compared to a net loss of $12.2 million in 2020, supported by a significant non-cash adjustment in derivative liabilities.
- Requested Type B meeting with the FDA to discuss Phase 3 trial design.
- Net income for Q3 2021 was $3.7 million, a significant improvement compared to a net loss of $12.2 million in Q3 2020.
- Cash runway extended into 2024, with $85.7 million in cash, cash equivalents, and short-term investments.
- General and administrative expenses increased to $3.0 million from $2.4 million in Q3 2020 due to rising share-based compensation.
- Non-GAAP net loss of $5.2 million for Q3 2021, although improved from a loss of $7.0 million in Q3 2020.
--Type B meeting with FDA requested to affirm design for additional Phase 3 trial needed for resubmission of NDA for Oral Sulopenem--
--Cash Runway into 2024--
--Iterum to host conference call today at 8:30am ET--
DUBLIN, Ireland and CHICAGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2021.
“We had a productive Type A meeting with the U.S. Food and Drug Administration (FDA) in the third quarter in which various potential paths forward to support potential resubmission of our New Drug Application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections (uUTI) were discussed. We have since requested a Type B meeting with the FDA with the goal of reaching agreement on the design of a Phase 3 trial for oral sulopenem for the treatment of uUTI that, if successful, could lead to a resubmission of our NDA,” said Corey Fishman, Chief Executive Officer.
Highlights and Recent Events
- Held Type A Meeting with FDA in Q3; Type B Meeting with FDA Requested: In September 2021, we had a Type A meeting with the FDA to discuss the steps required for potential resubmission of the NDA for oral sulopenem following receipt of the Complete Response Letter (CRL) in July 2021. We have requested a Type B meeting with the FDA to discuss the design of a potential new clinical trial to support such potential resubmission.
- Cash runway into 2024: Based on the current operating plan and subject to final determination of the design and planned conduct of potential additional clinical and non-clinical development of oral sulopenem, we believe that we are well positioned financially to fund operations into 2024 with our existing cash resources, which includes completing the proposed additional development of oral sulopenem to support, if successful, the resubmission of our NDA to the FDA. As of September 30, 2021, we had approximately 182.8 million ordinary shares outstanding.
Third Quarter 2021 Financial Results
As of September 30, 2021, Iterum had cash, cash equivalents and short-term investments of
Research and development expenses for the third quarter of 2021 were
General and administrative (G&A) expenses for the third quarter of 2021 were
Adjustments to the fair value of derivatives for the third quarter of 2021 were
For the third quarter of 2021, Iterum reported net income of
1 Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release
Upcoming Investor Presentation
- Corporate presentation at H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.
Conference Call Details
- Iterum will host a conference call today, Friday, November 12, 2021 at 8:30 a.m. Eastern Time. The dial-in information for the call is as follows: United States: 1 844 200 6205; International: 1 929 526 1599; Access code: 442364
About Iterum Therapeutics plc
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is currently advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation. Sulopenem also has an IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit http://www.iterumtx.com.
Non-GAAP Financial Measures
To supplement Iterum’s financial results presented in accordance with U.S. generally accepted accounting principles (“GAAP”), Iterum presents non-GAAP adjusted net loss and non-GAAP net loss per share to exclude from reported GAAP net income/(loss) and GAAP net income/(loss) per share, the interest expense associated with accrued interest on the Exchangeable Notes, payable in cash, shares or a combination of both upon exchange, redemption or at January 31, 2025 (“the Maturity Date”), whichever is earlier (
Iterum believes that the presentation of non-GAAP adjusted net loss and non-GAAP net loss per share, when viewed with its results under GAAP and the accompanying reconciliation, provides useful supplementary information to, and facilitates additional analysis by, investors, analysts, and Iterum’s management in assessing Iterum’s performance and results from period to period. These non-GAAP financial measures closely align with the way management measures and evaluates Iterum’s performance. These non-GAAP financial measures should be considered in addition to, and not a substitute for, or superior to, net income/(loss) or other financial measures calculated in accordance with GAAP. Non-GAAP adjusted net loss and non-GAAP net loss per share are not based on any standardized methodology prescribed by GAAP and represents GAAP net income/(loss), which is the most directly comparable GAAP measure, adjusted to exclude the interest expense associated with accrued interest on the Exchangeable Notes payable in cash, shares or a combination of both upon exchange, redemption or at the Maturity Date, whichever is earlier; the non-cash amortization of the Exchangeable Notes and Royalty-Linked Notes; one-time, non-capitalized financing transaction costs and the non-cash adjustments to the fair value of derivatives for the three and nine months ended September 30, 2021 and September 30, 2020. Because of the non-standardized definitions of non-GAAP financial measures, non-GAAP adjusted net loss and non-GAAP net loss per share used by Iterum Therapeutics in the accompanying press release and tables therein has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. A reconciliation of non-GAAP adjusted net loss to GAAP net income/(loss) and non-GAAP net loss per share to GAAP net income/(loss) per share have been provided in the tables included in the accompanying press release.
Forward Looking Statements
This press release contains forward-looking statements. These forward-looking statements include, without limitation, statements regarding Iterum’s plans, strategies and prospects for its business, including with respect to planned interactions and communications with the FDA and Iterum’s ability to reach agreement with the FDA on the design of any potential future clinical trials, Iterum’s expectations with regard to its ability to resolve the matters set forth in the CRL received by Iterum in July 2021 and obtain approval for oral sulopenem, the conduct of potential future clinical and non-clinical development of sulopenem, and the sufficiency of Iterum’s cash resources. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Iterum’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside Iterum’s control, including uncertainties inherent in the initiation and conduct of clinical and non-clinical development, including any potential additional clinical trials and non-clinical development that may be conducted in response to the CRL, availability and timing of data from such potential clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing or likelihood of regulatory filings and approvals, including any potential resubmission of the NDA, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of Iterum’s expectations regarding how far into the future Iterum’s cash on hand will fund Iterum’s ongoing operations including completing potential additional clinical and non-clinical development of oral sulopenem, the impact of COVID-19 and related responsive measures thereto, Iterum’s ability to maintain its listing on the Nasdaq Stock Market, risks and uncertainties concerning the outcome, impact, effects and results of Iterum’s evaluation of corporate, strategic, financial and financing alternatives, including the terms, timing, structure, value, benefits and costs of any corporate, strategic, financial or financing alternative and Iterum’s ability to complete one at all and other factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2021, and other documents filed with the SEC from time to time. Forward-looking statements represent Iterum’s beliefs and assumptions only as of the date of this press release. Except as required by law, Iterum assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com
| ITERUM THERAPEUTICS PLC | ||||||||||||||||
| Condensed Consolidated Statement of Operations | ||||||||||||||||
| (In thousands except share and per share data) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | (1,845 | ) | (3,937 | ) | (7,010 | ) | (18,723 | ) | ||||||||
| General and administrative | (3,029 | ) | (2,398 | ) | (10,698 | ) | (8,759 | ) | ||||||||
| Total operating expenses | (4,874 | ) | (6,335 | ) | (17,708 | ) | (27,482 | ) | ||||||||
| Operating loss | (4,874 | ) | (6,335 | ) | (17,708 | ) | (27,482 | ) | ||||||||
| Interest expense, net | (849 | ) | (4,183 | ) | (4,781 | ) | (10,854 | ) | ||||||||
| Financing transaction costs | — | (685 | ) | — | (2,815 | ) | ||||||||||
| Adjustments to fair value of derivatives | 9,783 | (644 | ) | (64,526 | ) | 1,023 | ||||||||||
| Other income, net | 33 | 68 | 167 | 27 | ||||||||||||
| Income tax expense | (352 | ) | (420 | ) | (534 | ) | (719 | ) | ||||||||
| Net income/ (loss) attributable to ordinary shareholders | $ | 3,741 | $ | (12,199 | ) | $ | (87,382 | ) | $ | (40,820 | ) | |||||
| Net income / (loss) per share attributable to ordinary shareholders – basic | $ | 0.02 | $ | (0.60 | ) | $ | (0.56 | ) | $ | (2.39 | ) | |||||
| Net income / (loss) per share attributable to ordinary shareholders – diluted | $ | 0.02 | $ | (0.60 | ) | $ | (0.56 | ) | $ | (2.39 | ) | |||||
| Weighted average ordinary shares outstanding – basic | 182,730,032 | 20,392,357 | 156,058,343 | 17,078,326 | ||||||||||||
| Weighted average ordinary shares outstanding – diluted | 202,257,112 | 20,392,357 | 156,058,343 | 17,078,326 | ||||||||||||
| Reconciliation of non-GAAP net income / (loss) to GAAP net loss | ||||||||||||||||
| Net income / (loss) - GAAP | $ | 3,741 | $ | (12,199 | ) | $ | (87,382 | ) | $ | (40,820 | ) | |||||
| Interest expense - accrued interest and amortization on Exchangeable Notes and Royalty-Linked Notes | 796 | 3,859 | 4,379 | 9,829 | ||||||||||||
| Financing transaction costs - not capitalized | — | 685 | — | 2,815 | ||||||||||||
| Adjustments to fair value of derivatives | (9,783 | ) | 644 | 64,526 | (1,023 | ) | ||||||||||
| Non-GAAP net loss | $ | (5,246 | ) | $ | (7,011 | ) | $ | (18,477 | ) | $ | (29,199 | ) | ||||
| Net income / (loss) per share attributable to ordinary shareholders – basic | $ | 0.02 | $ | (0.60 | ) | $ | (0.56 | ) | $ | (2.39 | ) | |||||
| Net income / (loss) per share attributable to ordinary shareholders – diluted | $ | 0.02 | $ | (0.60 | ) | $ | (0.56 | ) | $ | (2.39 | ) | |||||
| Non-GAAP net loss per share attributable to ordinary shareholders – basic and diluted | $ | (0.03 | ) | $ | (0.34 | ) | $ | (0.12 | ) | $ | (1.71 | ) | ||||
| ITERUM THERAPEUTICS PLC | ||||||||||||||||
| Condensed Consolidated Balance Sheet Data | ||||||||||||||||
| (In thousands) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| As of | As of | |||||||||||||||
| September 30, | December 31, | |||||||||||||||
| 2021 | 2020 | |||||||||||||||
| Cash, cash equivalents and short-term investments | $ | 85,711 | $ | 14,508 | ||||||||||||
| Other assets | 12,711 | 18,284 | ||||||||||||||
| Total assets | $ | 98,422 | $ | 32,792 | ||||||||||||
| Long-term debt, less current portion | $ | 6,134 | 22,462 | |||||||||||||
| Royalty-linked notes, less current portion | 18,403 | 13,389 | ||||||||||||||
| Derivative liabilities | 9,183 | 28,865 | ||||||||||||||
| Other liabilities | 12,254 | 18,635 | ||||||||||||||
| Total liabilities | 45,974 | 83,351 | ||||||||||||||
| Total shareholders' equity / (deficit ) | 52,448 | (50,559 | ) | |||||||||||||
| Total liabilities and shareholders' equity / (deficit) | $ | 98,422 | $ | 32,792 | ||||||||||||
FAQ
What was discussed in the recent meeting with the FDA regarding ITRM?
What is the financial status of Iterum Therapeutics as of Q3 2021?
How did Iterum's net income compare in Q3 2021 versus Q3 2020?
What were Iterum's research and development expenses in Q3 2021?
When is the next investor presentation for Iterum Therapeutics?
